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Abstract
Vascular endothelial growth factor (VEGF) is up-regulated during mesothelial to mesenchymal transition (MMT) and has
been associated with peritoneal membrane dysfunction in peritoneal dialysis (PD) patients. It has been shown that normal
and malignant mesothelial cells (MCs) express VEGF receptors (VEGFRs) and co-receptors and that VEGF is an autocrine
growth factor for mesothelioma. Hence, we evaluated the expression patterns and the functional relevance of the VEGF/
VEGFRs/co-receptors axis during the mesenchymal conversion of MCs induced by peritoneal dialysis. Omentum-derived
MCs treated with TGF-b1 plus IL-1b (in vitro MMT) and PD effluent-derived MCs with non-epithelioid phenotype (ex vivo
MMT) showed down-regulated expression of the two main receptors Flt-1/VEGFR-1 and KDR/VEGFR-2, whereas the co-
receptor neuropilin-1 (Nrp-1) was up-regulated. The expression of the Nrp-1 ligand semaphorin-3A (Sema-3A), a functional
VEGF competitor, was repressed throughout the MMT process. These expression pattern changes were accompanied by
a reduction of the proliferation capacity and by a parallel induction of the invasive capacity of MCs that had undergone an
in vitro or ex vivo MMT. Treatment with neutralizing anti-VEGF or anti-Nrp-1 antibodies showed that these molecules played
a relevant role in cellular proliferation only in naı¨ve omentum-derived MCs. Conversely, treatment with these blocking
antibodies, as well as with recombinant Sema-3A, indicated that the switched VEGF/VEGFRs/co-receptors axis drove the
enhanced invasion capacity of MCs undergoing MMT. In conclusion, the expression patterns of VEGFRs and co-receptors
change in MCs during MMT, which in turn would determine their behaviour in terms of proliferation and invasion in
response to VEGF.
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Introduction
Peritoneal dialysis (PD) is a therapeutic option for the treatment
of end-stage renal disease and is based on the use of the peritoneal
membrane (PM) as a permeable barrier across which ultrafiltration
and diffusion take place [1], [2]. Continuous exposure of the PM
to non-physiologic PD fluids, as well as episodes of peritonitis and
hemoperitoneum, may cause inflammation and injury to the PM,
which progressively undergoes denudation of the mesothelial cell
(MC) monolayer, submesothelial fibrosis and angiogenesis. These
structural alterations may lead to the loss of the PM dialytic
function [2], [3].
During long-term PD, MCs undergo a progressive loss of
epithelial phenotype and acquire myofibroblast-like characteristics
by a mesothelial-to-mesenchymal transition (MMT) process [2],
[4], [5]. It has been demonstrated that effluent-derived MCs still
retaining an epithelioid appearance ex vivo already show down-
regulated expression of E-cadherin and cytokeratins, suggesting
that the MMT of MCs starts soon after PD is initiated [4], [5].
MMT is a complex and stepwise process that is characterized by
the disruption of intercellular junctions, loss of apical-basolateral
polarity and acquisition of migratory and invasive properties. Cells
that have undergone MMT also acquire the capacity to produce
extracellular matrix components as well as inflammatory, fibro-
genic and angiogenic factors [6], [7], [8], [9]. We have previously
shown that effluent-derived MCs produce vascular endothelial
growth factor (VEGF) spontaneously and that the MMT process
of MCs is associated with strong VEGF up-regulation [10], [11].
Furthermore, we demonstrated that high levels of VEGF pro-
duction by effluent MCs correlated with high transport rates in PD
patients [11], [12].
VEGF is a key regulator of both physiologic and pathologic
angiogenesis [13], [14]. The biological effect of this growth factor
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is mediated by three VEGF receptors (VEGFRs): VEGFR-1/Flt-
1, VEGFR-2/KDR and VEGFR-3/Flt-4, which share similar
molecular structure and are composed by seven extracellular
immunoglobulin (Ig)-like domains, one transmembrane region,
and an intracellular tyrosine kinase domain that is activated via
ligand-triggered dimerization, leading to the induction of different
signal transduction pathways [15], [16]. The activity of VEGF is
also regulated by neuropilins (Nrps), a family of cell surface
glycoproteins composed by two members, Nrp-1 and Nrp-2, that
have about 45% amino acid identity and show conserved primary
structures. These proteins are constituted by, a large extracellular
domain, a single transmembrane domain and a short cytoplasmic
tail. The extracellular domain contains three structural motifs: two
CUB homology domains (a1/a2), two coagulation factor V/VIII
homology domains (b1/b2) and a mephrin/A5-protein/protein
tyrosine phosphatase m (MAM) domain (c) [17]. The short
cytoplasmic domain has no signalling motif but can interact with
several proteins [18].
Nrp-1 was first characterized as a receptor for the class III
semaphorins (Sema-3) in neurons mediating axon growth cone
collapse [19], [20]. Subsequently, it was also described as an
isoform-specific VEGF co-receptor expressed in endothelial and
tumour cells, enhancing VEGF binding to VEGFR-2 and its
bioactivity [21]. It has been described that Nrp-1 may also signal
independently of VEGFR-2 in endothelial cells to mediate VEGF-
triggered migration and adhesion [22], [23], [24], [25], [26]. The
a1/a2 domains of Nrp-1 are involved in Semaphorin 3A (Sema-
3A) binding, whereas VEGF binds to b1/b2 motifs [17], [27],
[28]. Sema-3A and VEGF are functional competitors in their
ability to bind Nrp-1 [17], [29], and promote ligand-triggered
Nrp-1 internalization [30]. More recent studies revealed that Nrp-
1 may also interact with other growth factors including hepatocyte
growth factor (HGF) [31], fibroblast growth factor (FGF) [32], and
transforming growth factor (TGF)-b1 [33], [34]. Besides neurons
and endothelial cells, Nrp-1 expression has been described in
many other cell types including MCs [35], [36], [37], [38], [39].
Importantly, Nrp-1 is frequently expressed by tumour cells and is
involved in their malignant progression [31], [34], [40], [41], [42],
[43], [44], [45], [46], [47], [48]. Nowadays, Nrps are considered
potential therapeutic targets in cancer but the complex mechan-
isms underlying the interaction of these molecules with multiple
ligands have not been fully elucidated so far. In this context, it has
been described that blocking Nrp-1 function reduced tumour
growth by inhibition of vascular remodelling, rendering vessels
more susceptible to anti-VEGF therapy [27], [48], [49], [50], [51].
It has been demonstrated that normal and malignant MCs
express VEGFRs and Nrps and that VEGF is an autocrine growth
factor for mesothelioma [37]. However, the role of VEGF/
VEGFRs/Nrps axis in peritoneal MCs during PD-induced MMT
is still unknown. Herein, we show that MCs change the expression
pattern of VEGFRs and co-receptors during MMT, which
determines a switch of the VEGF effect on MCs from a pro-
liferation response to an invasive response.
Materials and Methods
Ethics Statements
The protocol and informed consent were reviewed and
approved by the Ethics Committee of Clinic Investigation of the
‘Hospital Universitario de la Princesa’ (Madrid, Spain). All of the
patients signed the informed consent prior to the initiation of any
study-related activities. This research was carried out in accor-
dance with Good Clinical Practice guidelines, applicable regula-
tions, as well as the ethical principles that have their origin in the
Declaration of Helsinki.
Patients
We included 51 clinically stable PD patients in this study (30
men and 21 women), ranging in age from 25 to 78 years. The
causes of renal failure were diabetes (n = 16), chronic pyelone-
phritis (n = 12), glomerulonephritis (n = 10), nephrosclerosis
(n = 9), systemic disease (n = 3) and unknown cause (n = 1).
Thirty-four patients were treated with standard solution based
on glucose and lactate, containing high concentration of glucose
degradation products (GDPs) (Dianeal; Baxter Healthcare Corp.,
Deerfield, IL). Ten of these patients received one dwell per day
(generally overnight) with icodextrin-containing solution (Extra-
neal; Baxter) and 5 received one exchange with amino acid-
containing solution (Nutrineal; Baxter). Sixteen patients were
treated with low-GDPs solutions buffered with lactate in 11 cases
(Balance; Fresenius Medical Care, Bad Homburg, Germany) or
bicarbonate in 5 cases (BicaVera; Fresenius). Finally, 1 patient
received a combination of different solutions.
MCs from the dialysis effluents of these PD patients were
classified according to morphological characteristics and the
expression patterns of epithelial or mesenchymal markers
(Figure 1) into two groups: epithelioid (E) (n = 30) and non-
epithelioid (Non-E) (n = 21) [2], [11], [52], [53]. At the moment of
effluent-derived mesothelial cells (MCs) sampling, 43 patients were
on continuous ambulatory peritoneal dialysis and 8 were on
automatic peritoneal dialysis techniques.
The baseline characteristics of the patients and the differences
between the subgroups according to the phenotype of effluent-
derived MCs are shown in Table 1. Most patients (48 of 51)
received recombinant human erythropoietin during this study.
The mass transfer coefficients for urea and creatinine (Urea-MTC
and Cr-MTC) and the creatinine clearance (CCr) were measured
using standard methods [54]. Ultrafiltration (UF) capacity was
defined as a peritoneal exchange of 4 hours using 3.86% glucose
(214.3 mmol/L) [55]. Peritoneal glucose load was calculated by
the sum of glucose contained in each PD-fluid bag during the
whole time on PD. Eleven patients showed peritonitis, and one
experienced hemoperitoneum. MC cultures from effluent were
taken at least 3 months after the resolution of peritonitis or
hemoperitoneum episodes.
Isolation and Culture of Mesothelial Cells and Treatments
MCs from the dialysis effluents of the PD patients were isolated
as previously described [56]. To standardize effluent MC harvest-
ing, the cells were obtained from a long dwell (generally overnight)
with a PD fluid containing 2.27% glucose (Dianeal; Baxter).
Effluent MCs from patients treated with low-GDP liquids were
isolated from a long dwell with biocompatible fluids containing
2.3% glucose and buffered with lactate (Balance, Fresenius) or
with bicarbonate (BicaVera, Fresenius). Omentum-derived MCs
were obtained from patients that underwent unrelated abdominal
surgery as described elsewhere [56], [57]. All cells were cultured in
Earle’s M199 medium, supplemented with 20% fetal-calf serum
(FCS), 2% Hepes 1 M, 50 U/mL penicillin, 50 mg/mL strepto-
mycin and 2% Biogro-2 (Biological Industries, Beit Haemek,
Israel). The purity of effluent and omentum-derived MC cultures
was determined by the expression of standard mesothelial markers:
intercellular adhesion molecule-1, cytokeratins, and calretinine.
These MC cultures were negative for von-Willebrand factor,
CD31 and CD45, ruling out any contamination by endothelial
cells or macrophages [56], [58], [59].
VEGFRs and Mesothelial to Mesenchymal Transition
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To induce MMT in vitro, omentum-derived MCs were treated
for 72 hours with a combination of human-recombinant TGF-b1
(0.5 ng/mL) and IL-1b (2 ng/mL) (T+I) (R&D Systems, Inc,
Minneapolis, MN), which has been proven to be a good in vitro
model of MMT [4], [8], [11], [58], [59]. The cytokine doses used
were in the range of those detected in PD effluents, especially
Figure 1. Characterization of MMT in vitro and ex vivo. (A) Representative pictures of omentum-derived MCs, either untreated or treated with
TGF-b1 and IL-1b (MMT in vitro), and the two morphologies observed in confluent cultures of effluent-derived MCs: epithelioid and non-epithelioid.
(B) Transcript levels of mesenchymal markers were analyzed by quantitative RT-PCR (n = 11 Omentum, 11 Omentum T+I, 30 E and 21 Non-E). Results
show down-regulation of E-cadherin and up-regulation of snail expression during both in vitro and ex vivo MMT. The histograms also show
a significant up-regulation of N-cadherin and fibronectin expression in mesenchymal MCs compared to omentum and epithelioid MCs. Data are
depicted as mean value 6 SE. Symbols show statistical differences between groups.
doi:10.1371/journal.pone.0060776.g001
VEGFRs and Mesothelial to Mesenchymal Transition
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during peritonitis episodes [60], and were similar to those used in
previous studies [4], [8], [11], [52], [53], [58], [59], [61]. We
included 31 healthy donors of omental tissue for the study, of
which 11 donors were used for QT-PCR analysis and 20 for
proliferation, invasion and immunofluorescence assays. Further-
more, we included 15 additional clinically stable PD patients
randomly selected to obtain effluent MCs for proliferation and
invasion assays, whose baseline characteristics where not consid-
ered for these experiments.
Figure 2. The expression of FSP-1 is up-regulated during in vitro and ex vivoMMT. The expression of FSP-1 and cytokeratin was analyzed in
omentum and effluent-derived MCs by immunofluorescence using confocal microscopy. MCs were double stained for cytokeratin (green) and FSP-1
(red). Nuclei were stained with DAPI. Pictures show in vitro a Cyt+++/FSP1- staining for normal MCs (a–c), and Cyt+/FSP1++ for MCs treated with TGF-
b1 and IL-1b (d–f). Ex vivo, pictures show Cyt++/FSP1+ staining for epithelioid MCs (g–i) and Cyt+/FSP1++ staining for non-epithelioid MCs (j–l)
proving the mesenchymal conversion of MCs. Data are representative of 5 samples for each condition from PD patients and omentum samples
included in the study.
doi:10.1371/journal.pone.0060776.g002
VEGFRs and Mesothelial to Mesenchymal Transition
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Reagents and Antibodies
Recombinant human TGF-b1, IL-1b and Sema-3A were
purchased from R&D Systems (100-B, 201-LB and 1250-S3,
respectively; Minneapolis, MN,). Blocking monoclonal antibody
against VEGF (MAB293, R&D Systems), and antibodies against
the VEGF-binding motif or the Sema-3A-binding motif of Nrp-1
(Np-1b and Np-1a, respectively; Genentech, San Francisco, USA)
[49], were used in the proliferation and invasion assays. Mono-
clonal antibodies IgG2a and IgG2b (Sigma-Aldrich, St Louis,
MO, USA) were employed as isotype controls. Pilot studies were
performed to establish optimal antibodies and recombinant
protein dosages. For Western blotting anti-Nrp-1 rabbit mono-
clonal antibody (ab81321, Abcam, Cambridge, UK), anti-
VEGFR-2 mouse monoclonal antibody (sc-316, Santa Cruz
Biotechnology, Santa Cruz, CA) and anti-tubulin mouse mono-
clonal antibody (T-5168, Sigma-Aldrich) were used. For immu-
nofluorescence, the same antibodies against Nrp-1 and VEGFR-2
used in Western blot were employed. Cells were also stained with
Figure 3. Transcript levels of VEGF receptors/co-receptors during in vitroMMT.mRNA levels of VEGF receptors/co-receptors were analyzed
by quantitative RT-PCR. The results represent the relative mRNAs expression of VEGF receptors in omentum-derived MCs treated with TGF-b1 plus IL-
1 b (Omentum T+I) compared with untreated MCs (Omentum NT). The data are depicted as mean value 6 SE of omentum samples from 11 healthy
donors. (A, B and D) The histograms show a down-regulation in expression of receptors VEGFR-1 (p = 0.005) and VEGFR-2 (p = 0.0005) and up-
regulation of co-receptor Nrp-1 (p = 0.004). (C and E) The expression of VEGFR-3 and Nrp-2 did not show significant differences.
doi:10.1371/journal.pone.0060776.g003
VEGFRs and Mesothelial to Mesenchymal Transition
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anti-VEGF rabbit polyclonal antibody (ab46154, Abcam), anti-
Pan cytokeratin mouse monoclonal antibody (c-1801, Sigma-
Aldrich) and anti-FSP-1 (A-5114, Dako, Glostrup, Denmark).
Secondary antibodies (conjugated to Alexa Fluor 568 and Alexa
Fluor 488) were from Molecular Probes (Life Technologies, USA).
For immunohistochemistry anti-Nrp-1 mouse monoclonal anti-
body (sc-5307, Santa Cruz Biotechnology) and mouse monoclonal
anti-Pan cytokeratin (c-2931, Sigma-Aldrich) were employed.
Real-time Quantitative PCR Analysis
Total RNA was extracted using TRI ReagentH (Ambion, Inc.,
Austin, TX) and following manufacturer’s recommendations.
Figure 4. Transcript levels of VEGF receptors/co-receptors during ex vivo MMT. The histograms represent the relative mRNA expression of
VEGF receptors/co-receptors in non-epithelioid effluent-derived MCs (Non-E, n = 21) compared with epithelioid effluent-derived MCs (E, n = 30). The
data are depicted as mean value 6 SE of effluent samples from 51 PD patients. (A, B and D) Similar results to those of in vitro MMT: a significant
down-regulated expression of receptors VEGFR-1 (p = 0.0009) and VEGFR-2 (p,0.0001) and up-regulation of co-receptor Nrp-1 (p = 0.001). (C and E)
The expression of VEGFR-3 and Nrp-2 did not show variation.
doi:10.1371/journal.pone.0060776.g004
VEGFRs and Mesothelial to Mesenchymal Transition
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Complementary DNA was obtained from 2 mg of total RNA by
reverse transcription (RNA PCR Core Kit; Applied Biosystems,
Foster City, CA). Quantitative RT-PCR was carried out in a Light
Cycler 2.0 using a SYBR Green kit (Roche Diagnostics GmbH,
Mannheim, Germany) and specific primers for VEGFR-1/Flt-1,
VEGFR-2/KDR and VEGFR-3/Flt-4, Nrp-1, Nrp-2, Sema-3A,
E-cadherin, N-cadherin, snail, fibronectin and histone H3 (Table
S1). Amplification values were normalized with respect to the
value obtained for H3.
Enzyme-linked Immunoassay
Albumin, VEGF and Sema-3A concentrations were determined
by using standard enzyme-linked immunoassay (ELISA) kits
(Abcam; R&D Systems; UscnK Life Science, USA; respectively).
For analysis of VEGF levels in supernatants, the media of
confluent MC cultures in the first passage was replaced with fresh
media and 18 hours later supernatants were collected and stored at
–80uC until their analysis. The results were normalized with total
protein of cell lysates and depicted as picograms per milligrams
(pg/mg). For VEGF concentration in effluents from PD patients,
15 ml of each bag of effluents were collected and stored at –80uC
until their analysis. Results were represented as picograms per
millilitre (pg/mL).
For Sema-3A concentration in effluents from PD patients, the
dialysates were concentrated as previously described [62], using
commercial concentrators (Amikon Ultra-15, Millipore). The
concentration factor was defined as the albumin concentration
in the concentrate divided by the albumin concentration in the
original effluent sample. Results were represented as pg/mL.
Figure 5. Expression levels and cellular distribution of Nrp-1 and VEGFR2 proteins during in vitro and ex vivoMMT. (A) Western blots
show the expression levels of Nrp-1 and VEGFR-2 in total cell lysates during in vitro and ex vivo MMT. Expression of a-tubulin is employed as a loading
control. Human umbilical vein endothelial cells (HUVEC) are used as a positive control. The histograms depict the quantification of Nrp-1 and VEGFR2
levels compared with a-tubulin. Data are representative of 5 samples for each condition from PD patients and omentum samples included in the
study. (B) The expression of Nrp-1, VEGFR-2, and VEGF was analyzed by immunofluorescence microscopy in omentum and effluent-derived MCs. MCs
were double stained for Nrp-1 (green) and VEGFR-2 (red), and single stained for VEGF (green). Nuclei were stained with DAPI. Nrp-1 and VEGF show
a membrane distribution in omentum and epithelioid MCs (b, c, h, i). During in vitro (e, f) and ex vivo (k, l) MMT both proteins change their
localization and are internalized. The expression of VEGFR-2 is down-regulated but it does not show differences in localization during in vitro (a, d)
and ex vivo (g, j) MMT.
doi:10.1371/journal.pone.0060776.g005
Figure 6. Nrp-1 immunohistochemical analysis in peritoneal human biopsies. The expression of Nrp-1 and the mesothelial marker
cytokeratin was analyzed in human peritoneal specimens by immunohistochemistry. Positive cells for antibodies used (Nrp-1 and Cytokeratin) show
brown staining. Nuclei are counterstained in blue. (a, b) Control peritoneal tissue, with a conserved mesothelial cell monolayer showing an
epithelioid morphology (with a 20X objective). These cells show weak expression of Nrp-1 and a marked staining for cytokeratin (arrows). No
expression of these proteins was observed in the submesothelial area (region under mesothelial monolayer) (c, d) Fibrotic tissue sample from PD
patient showing the loss of mesothelial monolayer and invading spindle-like mesothelial cells in submesothelial area (with a 40X objective). These
cells present a strong staining for Nrp-1 (c), and are also positive for cytokeratin (d) (arrows). Pictures are representative of 5 cases of PD patient
samples and 4 of control samples.
doi:10.1371/journal.pone.0060776.g006
VEGFRs and Mesothelial to Mesenchymal Transition
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Western Blotting
MC cultures were lysed in RIPA buffer (1% sodium
deoxycholate, 0.1% sodium dodecyl sulfate) plus a phosphatase
and protease inhibitor cocktail (Pierce) and total protein was
quantified by protein assays kit (Pierce). Equal amounts of
denatured proteins (30–40 mg) from each sample were resolved
by 8–10% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis under reducing conditions. Proteins were transferred on
nitrocellulose membranes, which were then blocked with 5%
nonfat milk in TBS-Tween buffer for 1 hour and incubated with
specific antibodies against Nrp-1, VERGFR-2 and tubulin in 0.5%
milk in TBS-Tween overnight at 4uC. These antibodies were
detected with a peroxidase conjugated goat anti-mouse and
donkey anti-rabbit antibodies (Pierce, Rockford, IL, USA), and
then were visualized with enhanced chemiluminescence (ECL)
detection kit (Pierce, Rockford, IL, USA). Blot images were
acquired with GS-710 Imaging Densitometer (Bio-Rad, Hercules,
CA) and analyzed with Quantify-One software (Bio-Rad).
Confocal Microscopy and Immunofluorescence
Cells were fixed for 10 minutes in 4% paraformaldehyde and
permeabilized 10 minutes in 0.1% NP-40. In all cases, 5% goat
serum was applied for 20 minutes to block non-specific unions.
Cells were stained for Nrp-1 (labeled with Alexa Fluor 488),
VEGFR-2 (labeled for Alexa Fluor 568) and VEGF (labeled with
Alexa Fluor 488) and mounted with fluorescent mounting media
(Dako). Confocal images were acquired with a LSM710 Zeiss
Confocal Microscope (with a 40X objective).
Biopsy Processing and Immunohistochemical Analysis
Parietal peritoneum biopsies from PD patients were obtained
from the anterior abdominal wall by surgeons during renal
transplantation, insertion or removal of the PD catheter, or
because of incidental abdominal conditions. Normal control
samples of parietal peritoneum from non-uremic patients sub-
jected to elective surgeries were also included in this study. Written
consent was obtained from patients prior to obtaining the
peritoneal samples. Tissue samples were routinely fixed in
neutral-buffered 3.7% formalin (pH 7.3) during 12–24 hours.
Afterwards, samples were dehydrated and embedded in paraffin to
obtain sections 3–4 mm thick. Deparaffinised sections were stained
with Haematoxylin-Eosin and Masson’s trichrome to analyze the
histological characteristics of each specimen. Samples from 5 PD
patients with evident sign of submesothelial fibrosis and 4 controls
were included in this study.
For immunohistochemistry, samples were incubated with 3%
hydrogen peroxide in methanol to block endogenous peroxidase
activity. Antigen retrieval was performed by heating samples in
citrate buffer (pH 6). Monoclonal anti-Nrp-1 (Santa Cruz Bio-
technology) and anti-Pan-cytokeratin antibodies (Dako) were
applied to detect the antigens by means of a dextran-polymer
conjugate technique (EnVision+, Dako). The reactions were
visualized by diaminobenzidine chromogen (brown) and tissue
sections were finally counterstained with a nuclear haematoxylin
staining (blue). Morphological characteristics were studied as
previously described [4], [11].
Proliferation Assays
For proliferation assays, 104 cells/well of effluent- or omentum-
derived MCs, with either epithelioid or non-epithelioid pheno-
types, were seeded into 96-well plates and cultured at 37uC and
5% CO2 for 48 hours. Cells were then pulsed with [3H]-thymidine
(1 mCi per well) for 16–18 hours and lysed with Filter Mate Cell
Harvester (Perkin Elmer, Turku, Finland). Radioactivity was
determined for 1 minute in a basic beta liquid scintillation counter
(Perkin Elmer). For proliferation-blocking experiments, anti-
VEGF (0.5, 1 or 10 mg/mL), anti-Np-1b (10 mg/mL), anti-Np-
1a (10 mg/mL), and isotype controls (10 mg/mL) were added in
fresh medium eight hours prior to [3H]-thymidine addition. Each
experiment was carried out in triplicate, and at least 8 experiments
were performed.
Figure 7. Analysis of the expression levels of VEGF and Sema3A during the MMT process. (A and B) The expression of VEGF in MC
culture supernatants during in vitro (n = 11, p = 0.006) and ex vivo (n = 51, p,0.0001) MMT was analyzed by ELISA. (C) VEGF secretion in effluents of
PD patients draining MCs with different phenotypes was also analyzed by ELISA (E, n = 16 and Non-E, n = 11; p = 0.04). (D) Correlation between VEGF
levels ex vivo and effluents of PD patients (r = 0.578, p,0.0001) (E and F) Sema-3A mRNA expression, in both in vitro (p = 0.006) and ex vivo
(p = 0.0002) MMT, was analyzed by quantitative RT-PCR. (G) Sema-3A secretion in PD effluents (n = 16 E and 11 Non-E; p = 0.02). Box Plots represent
25% and 75% percentiles, median, minimum and maximum values. Numbers above boxes and histograms depict mean 6 SE.
doi:10.1371/journal.pone.0060776.g007
Table 1. Baseline characteristics of PD patients with different phenotypes of mesothelial cells.
Parameters Studied population (n=51) Mesothelial Cells Phenotype P
Epithelioid
(n=30)
Non-Epithelioid
(n=21)
Time on PD(months) 7.6166.52 6.5566.47 9.4166.37 0.04
CCr (mL/min) 4.8263.50 5.7463.56 3.5063.00 0.02
Glucose load (Kg) 22.85628.26 24.55633.75 20.41618.27 NS
Urea-MTC (mL/min) 23.2066.95 23.7468.06 22.4365.05 NS
Cr-MTC (mL/min) 10.8563.13 10.3962.72 11.5063.60 NS
UF 3.86% (mL)* 505.906171.58 508.806181.64 501.766160.40 NS
Nu Peritonitis 11 from 51 2 from 11 9 from 11 0.03
VEGF (pg/mg) 20878.6464185.47 5328.6361005.32 43092.9267894.40 0.0001
CCr: creatinine clearance. MTC: mass transfer coefficient. UF: ultrafiltration after a 4-hour dwell with glucose 3.86%. VEGF: vascular endothelial growth factor. Values
represent mean 6 SD for median clinical parameters or mean 6 SE for supernatant VEGF.
doi:10.1371/journal.pone.0060776.t001
VEGFRs and Mesothelial to Mesenchymal Transition
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Invasion Assays
Invasion assays were performed in a 24-well insert system
(Costar, Cambridge, MA). The filters, 8 mm pore size, were pre-
coated with 40 mL of 300 mg/mL solution of collagen type I
(PureCol, Inamed, Fremont, Canada) allowing to gel overnight at
37uC. Then, 36104 starved MCs/well were added into the upper
chamber. As a chemotactic stimulus, 5% FCS was added into the
lower chamber in 600 mL of medium. Cells were allowed to
invade for 24 hours at 37uC and 5% CO2. Transwells were then
fixed in 4% formaldehyde. After removing the gel and non-
invading cells from the upper face of the membrane with a cotton
swab, filters were cut out and nucleus of invading cells were
stained with 49,6-diamidine-29-phenylindole dihydrochloride
(DAPI). Invading cells were counted in ten fields per sample using
a fluorescence microscope (with a 40X objective). For invasion-
blocking experiments, MCs were pre-incubated during 30 minutes
at 4uC with recombinant Sema-3A (150 nM), anti-VEGF (0.5, 1
or 10 mg/mL), anti-Np-1b (10 mg/mL), anti-Np-1a (10 mg/mL),
isotype controls (10 mg/mL), before seeding in transwell units. At
least 8 experiments were carried out in duplicate.
Statistical Analysis
Experimental data in Figures and Tables are depicted as mean
6 standard error (SE). Clinical data of patients included in the
study are given as mean 6 standard deviation (SD). To assess the
changes produced in MCs by in vitro MMT, induced by the
treatment with TGF-b1+IL-1b, the data was analyzed using
a Paired test. Comparison between data groups was performed
using the non-parametric Mann Whitney rank-sum U test,
Spearman regression analysis, Chi-square and 2-tail Fisher exact
test. P values less than 0.05 were considered statistically significant.
We used SPSS Inc, version 15 (Chicago, IL) and GraphPad Prism
4.0 (La Jolla, CA).
Results
Characterization of Mesothelial to Mesenchymal
Transition (MMT)
For this study, we included omentum MCs from 11 donors that
underwent unrelated abdominal surgery and effluent-derived MCs
from 51 PD patients. To characterize the MMT process, we first
identified the different morphologies of confluent MC cultures
(Figure 1A). The effluent-derived epithelioid MCs showed
cobblestone morphology similar to that of normal MCs (omen-
tum), and effluent-derived non-epithelioid MCs showed a fibro-
blast-like phenotype similar to that of omentum treated with TGF-
b1 and IL-1b (omentum T+I). Then, the cells were lysed for RNA
extraction and we performed quantitative RT-PCR in order to
study the transcript level expression of the epithelial marker E-
cadherin and the mesenchymal markers N-cadherin, fibronectin
and snail (Figure 1B). We observed a strong down-regulation of
E-cadherin and up-regulation of its repressor, snail, during both
in vitro and ex vivo MMT. We also observed a significant up-
regulation of N-cadherin and fibronectin expression in mesenchy-
mal MCs compared to omentum and epithelioid MCs. These data
demonstrated the mesenchymal conversion of MCs.
To further characterize the MMT process, we studied the
expression of fibroblast specific protein-1 (FSP-1), a mesenchymal
marker, and the expression of cytokeratin (Cyt), a mesothelial
marker, by immunofluorescence and confocal analysis (Figure 2).
We observed a Cyt+++/FSP1- staining for normal MCs (Figure 2
a–c), and Cyt+/FSP1++ for MCs treated with TGF-b1 and IL-1b,
as a consequence of in vitro mesenchymal conversion (Figure 2 d–
f). In effluent-derived MCs cultured ex vivo, we observed a Cyt++/
FSP1+ staining for epithelioid MCs (Figure 2 g–i). In this case
cytokeratin staining showed less intensity than normal MCs and
FSP-1 was also expressed, suggesting that epithelioid MCs were
undergoing an early MMT. Non-epithelioid MCs showed Cyt+/
FSP1+++ staining, indicating a more advanced mesenchymal
transformation (Figure 2 j–l).
Switch of VEGF Receptors/co-receptors during in vitro
and ex vivo Mesothelial to Mesenchymal Transition
It has been shown that the expression of VEGFR-1/Flt-1,
VEGFR-2/KDR, Nrp-1 and Nrp-2 remains unchanged during
the malignant transformation of MCs (e.g. mesothelioma) [37].
However, the expression patterns of VEGFRs and co-receptors
throughout the mesenchymal conversion of MCs have not been
analyzed so far. Thus, we analyzed by quantitative RT-PCR the
expression levels of VEGFR-1/Flt-1, VEGFR-2/KDR, VEGFR-
3/Flt-4, Nrp-1 and Nrp-2 throughout in vitro and ex vivo MMT.
Treatment of omentum MCs with TGF-b1 plus IL-1b (in vitro
MMT) significantly down-regulated the expression of VEGFR-1
and VEGFR-2 (Figures 3A and 3B) and up-regulated the
expression of the co-receptor Nrp-1 (Figure 3D). The expression
of VEGFR-3 and Nrp-2 did not show statistical differences
(Figures 3C and 3E). Similarly, comparison of effluent-derived
MCs with different phenotypes (ex vivo MMT) showed significant
down-regulation of VEGFR-1 and VEGFR-2 (Figures 4A and
4B) and up-regulation of Nrp-1 (Figure 4D) in non-epithelioid
cells when compared with epithelioid cells. Again, the expression
of VEGFR-3 and Nrp-2 did not show statistical differences
(Figures 4C and 4E). Thus, these results evidence the switch of
the expression patterns of VEGFRs and co-receptors throughout
in vitro and ex vivo MMT.
These alterations are inherent features of the mesenchymal
conversion of MCs and not a result of the treatment with TGF-b1
plus IL-1b. We induced a reversible in vitro MMT treating MCs
Table 2. Differences between low and high peritoneal
transporters.
Cr-MTC ,11
mL/min (n =29)
Cr-MTC $11
mL/min(n =22) P
Urea-MTC (mL/min) 21.2363.53 25.8069.30 0.02
Albumin (g/dL) 3.6460.46 3.4660.36 0.04
UF rate (3.86%) 574.666180.61 415.276107.10 0.0001
Glucose load (Kg) 20.99633.56 25.29619.72 0.01
Nu peritonitis 4 from 11 7 from 11 NS
VEGF (pg/mg) 14319.4364242.77 29524.8667667.62 0.01
VEGFR-1 (R.U) 2.0060.73 0.9360.36 NS
VEGFR-2 (R.U) 3.7360.65 1.5260.35 0.005
VEGFR-3 (R.U) 0.2260.02 0.2460.05 NS
Nrp-1 (R.U) 6.2160.64 8.2961.24 0.14 (NS)
Nrp-2 (R.U) 0.7460.08 0.7560.10 NS
Sema-3A (R.U) 5.5960.48 4.0660.43 0.025
Statistic differences between the groups of low, low-average (Cr-MTC ,11 mL/
min, range 4.3–10.9) and high, high-average (Cr-MTC $11 mL/min, range 11.3–
18.3) peritoneal transporters. R.U. mRNA relative units. Values represent mean
6 SD for median clinical parameters or mean 6 SE for experimental data.
doi:10.1371/journal.pone.0060776.t002
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with TGF-b1 plus IL-1b for 72 hours, and after that, we replaced
the media without the cytokines for another 24 hours. We
observed that MCs reverted the mRNA levels of VEGFR and co-
receptors after removal of the stimuli (Figure S1).
The Expression and Subcellular Localization of VEGFR-2
and Nrp-1 Proteins Change during MMT
We studied the expression of Nrp1 and VEGFR-2 by Western
blot to confirm the data obtained by quantitative RT-PCR. Up-
regulated expression of Nrp-1 and down-regulated expression of
VEGFR-2 proteins were observed during both in vitro MMT
(omentum vs. omentum T+I) and ex vivo MMT (epithelioid vs.
non-epithelioid) (Figure 5A). We also studied the cellular
distribution of both proteins by immunofluorescence and we
observed that Nrp-1 showed different localization depending on
the cell phenotype. In epithelial-like MCs (omentum and effluent
epithelioid cells), Nrp-1 was mainly localized in the membrane
(Figure 5B b, h), whereas in mesenchymal-like MCs (omentum
T+I and effluent non-epithelioid cells) the distribution was
cytoplasmic, suggesting its internalization (Figure 5B e, k). In
contrast, VEGFR-2 had a cytoplasmic distribution in all cell types
(Figure 5B a, d, g, j). MCs stained with anti-VEGF showed
a similar pattern of expression and distribution to cells stained with
anti-Nrp-1 (Figure 5B c, f, i, l). Moreover, pictures showed
different intensity patterns for Nrp-1 and VEGFR-2 during MMT,
confirming data previously observed by Western blot.
To confirm in vivo the local up-regulation of Nrp-1 by non-
epithelioid MCs, peritoneal biopsies from PD patients and controls
(non-renal patients) were subjected to immunohistochemical
analysis. Submesothelial fibroblasts from the control group did
not express Nrp-1 (Figure 6 a), and a weak expression of this co-
receptor was confined to the surface of the MC monolayer. In
contrast, peritoneal biopsies from PD patients, with evident signs
of peritoneal fibrosis, showed up-regulated expression of Nrp-1 in
spindle-like cells embedded in the fibrotic stroma, located mainly
in the upper submesothelial area (Figure 6 c). Serial sections from
the same peritoneal samples showed expression of cytokeratin
overlapping with Nrp-1 in the compact zone from PD patients
(Figure 6 d). The controls showed cytokeratin staining in the
mesothelium but not in the submesothelial area (Figure 6 b).
Increase of the VEGF/Sema-3A Ratio throughout the
MMT Process
A previous study from our group described that MMT is
associated with strong up-regulation of VEGF expression [10]. In
the present study, we confirmed the induction of VEGF secretion
to culture supernatants in omentum MCs treated with TGF-b1
plus IL-1b (in vitro MMT) and in effluent MCs with non-
epithelioid phenotype (ex vivo MMT) (Figures 7A and 7B).
Furthermore, we determined the levels of VEGF secreted in the
dialysates of PD patients and we observed higher levels of VEGF
in effluents of patients that drained non-epithelioid MCs than in
effluents with epithelioid MCs (Figure 7C). Moreover, we found
a significant correlation between VEGF levels secreted ex vivo and
VEGF levels secreted in effluents (Figure 7D).
On the other hand, it has been shown that Sema-3A might act
as a functional competitor of VEGF-driven cell responses through
the competition for Nrp-1 binding [37], [63]. Thus, we measured
Sema-3A mRNA expression throughout the MMT process.
Significant down-regulation of Sema-3A-encoding transcript took
place in both in vitro and ex vivo MMT (Figures 7E and 7F). We
also analyzed the concentration of Sema-3A in the effluents. We
found significant lower levels of this protein in effluents that
drained non-epithelioid MCs. (Figure 7G). In addition, the
expression of VEGF and Sema-3A showed a significant negative
correlation (Figure S2). These data demonstrate that the VEGF/
Sema-3A ratio increases throughout the MMT process.
The Change of the VEGF/VEGFRs/Nrp Axis is Associated
with Peritoneal Functional Decline in PD Patients
We analyzed the baseline characteristics of PD patients included
in this study and the differences between subgroups according to
the phenotype of effluent-derived MCs (Table 1). Significant
differences in the time on PD, the CCr and ex vivo production of
VEGF were found between epithelioid and non-epithelioid
subgroups of MCs. Nine of the 11 patients who experienced
peritonitis, and the patient that suffered hemoperitoneum, drained
non-epithelioid MCs in their effluents (p = 0.03). These data
suggest that MCs with non-epithelioid phenotype appear at early
stages of peritoneal membrane deterioration, even before ultra-
filtration failure has been established.
An elevated mass transport coefficient for creatinine (Cr-MTC)
is a clinical marker for peritoneal functional decline, which is
related to the augmented vessel number and is associated with
increased production of VEGF by MCs [10]. Thus, we subdivided
the PD patients into 2 groups according to peritoneal transport
characteristics: Cr-MTC ,11 mL/min (low and low-average
transporters) and Cr-MTC $11 mL/min (high and high-average
transporters) [7], [10]. As expected, the high transporter group
showed a significant increase of urea-MTC and glucose load and
a significant decrease of ultra-filtration (Table 2). In addition, Cr-
MTC seemed to be associated with effluent MC phenotype; 30%
of patients (9 of 30) with epithelioid MCs in their effluent showed
Cr-MTC $11, whereas 62% of patients (13 of 21 patients) with
non-epithelioid MCs showed Cr-MTC $11 (two tails Fischer’s
exact test; r = 0.395, p = 0.04) (Table S2). In agreement with our
previous results [10], effluent-derived MCs from high transporters
produced significantly higher ex vivo amounts of VEGF than MCs
from low transporters (Table 2). In addition, we observed
a significant correlation between the high peritoneal transport
status and the down-regulation of VEGFR-2 and Sema-3A
mRNAs ex vivo. The high transporter group showed augmented
expression of Nrp-1-encoding mRNA, although it did not reach
statistical significance (Table 2). Of note, the increased expression
of Nrp-1 had a significant correlation with the time on PD
(p = 0.001). These data indicated that the peritoneal functional
decline was associated to changes of MC phenotype and to
changes of VEGF/VEGFRs/Nrp axis.
Figure 8. Treatment with anti-VEGF and anti-Np1b blocking antibodies interferes with the proliferation of mesothelial cells. (A) The
proliferation capacity of MCs throughout in vitro and ex vivo MMT was analyzed by the incorporation of [3H]-thymidine (n = 20). Bar graphic depicts
the radioactivity emitted (c.p.m.) in each condition. Data are depicted as mean value 6 SE. Symbols show statistical differences between groups. (B
and E) Effect of anti-VEGF (n = 10) and anti-Np1b antibodies (n = 8), or IgG isotype control antibody on the proliferation capacity of omentum-derived
MCs, either untreated (B) or treated with TGF-b1 plus IL-1b (C); and on the proliferation capacity of effluent-derived MCs with epithelioid (D) or non-
epithelioid phenotype (E). Bar graphics represent proliferation percentage of treatments over control cells. Data are depicted as mean value 6 SE.
Symbols show statistical differences between groups.
doi:10.1371/journal.pone.0060776.g008
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Effects of VEGF- and Nrp-1-blocking Antibodies on MC
Proliferation and Invasion
We hypothesized that VEGF might establish loops in MCs to
control key processes, such as proliferation and/or invasion. Our
results suggest that the pair VEGF/Nrp-1 appear to gain relevance
throughout MMT, given that both are up-regulated during the
whole process. Of note, the up-regulated expression of VEGF and
Nrp-1 showed a strong correlation (Figure S2). Thus, we
investigated whether these two molecules played a major role in
proliferation and/or invasion of MCs during the MMT process.
Analysis of the proliferation capacity showed that throughout
in vitro and ex vivo MMT there was growth arrest of MCs
(Figure 8A). Blocking of endogenously produced VEGF with
a specific antibody resulted in significant inhibition of the
proliferation of omentum MCs (Figure 8B). In contrast, the
lower proliferation capacity of mesenchymal-like MCs (T+I-
treated omentum MCs and Non-E effluent MCs) was not affected,
or only marginally affected, by treatment with anti-VEGF
(Figures 8C and 8E). Surprisingly, the proliferation capacity of
effluent MCs with epithelioid phenotype, which was similar to that
of omentum MCs, was only slightly affected by the VEGF-
blocking antibody (Figure 8D). These data suggest that endog-
enous VEGF only plays a role on cellular proliferation in naı¨ve
epithelial-like MCs, but not in MCs at any stage, early or late, of
the mesenchymal conversion. Treatment with blocking anti-Np-1b
antibody inhibited cellular proliferation to a similar extent (25 to
30%) in MCs with both epithelial and mesenchymal phenotypes
(Figures 8B to 8E), suggesting that Nrp-1 mediated not only the
VEGF-dependent but also the VEGF-independent proliferation
response. In this context, anti-Np-1a antibody, which did not
interfere in VEGF-Nrp-1 interaction, also partially inhibited the
proliferation of mesenchymal-like MCs (data not shown).
Invasion assays using omentum MCs demonstrated that in vitro
MMT enhanced the invasion capacity. On the other hand,
effluent-derived MCs with both epithelioid and non-epithelioid
phenotypes showed increased invasion capacity when compared
with omentum-derived MCs (Figure 9A). Treatment of omentum
MCs with anti-VEGF and anti-Np-1b antibodies significantly
inhibited the invasion capacity, and co-treatment with both
antibodies had no additive effect (Figure 9B). Treatment of
MCs that were at any stage of the MMT process including
epithelioid MCs from effluents with anti-VEGF and anti-Np-1b
antibodies showed also an important significant inhibition of the
invasion capacity, and co-treatment with both antibodies had co-
operative effects (Figures 9C to 9E). Treatment of omentum-
and effluent-derived MCs with anti-Np-1a, which did not block
the VEGF-Nrp-1 interaction [49], showed partial (Figures 9B
and 9D) or no statistically significant effects on cellular invasion
(Figures 9C and 9E). In addition, treatment of MCs with
recombinant Sema-3A, which has been shown to compete with
VEGF for binding to Nrp-1, resulted in a statistically significant
diminished invasion capacity, reinforcing the notion that the
interaction of VEGF with Nrp-1 participated, at least partially, in
MC invasion (Figures 9B to 9E).
Discussion
The presence of MCs that have undergone a MMT in the
effluent and in the peritoneal tissue of PD patients was first
demonstrated in a landmark paper published in 2003 [4]. MCs
with mesenchymal phenotype acquire the capacity to synthesize
extracellular matrix components as well as pro-inflammatory and
pro-angiogenic factors [2]. During the last few years, emerging
evidence has suggested that the mesenchymal conversion of MCs
is an important event for structural and functional peritoneal
deterioration [7], [10], [64], [65]. In this context, we have
previously shown that during the MMT process there is a strong
up-regulation of VEGF and that high levels of VEGF production
by effluent-derived MCs correlated with high transport rates in PD
patients [10]. In this study we show that, not only VEGF
expression levels, but also the whole VEGF/VEGFRs/co-
receptors axis, is associated with high peritoneal transport status.
Peritoneal fibrosis is the most common structural change
observed in PD patients, and it has been considered the main
cause for the progressive functional decline of the peritoneum.
However, in parallel with fibrosis, the peritoneum may also
experiment an increase in capillary number (angiogenesis) in
response to PD. Some reports have evidenced that enhancement
of peritoneal vasculature and vessel permeability appear to be
responsible for an increase in solute transport across the peritoneal
membrane [66], [67]. It is generally accepted that local production
of VEGF by MCs during PD may exert paracrine effects on
endothelial cells to induce peritoneal angiogenesis and functional
decline [10], [62], [68], [69]. Furthermore, VEGF has been shown
to inhibit endothelial to mesenchymal transition [70], [71].
Therefore, it is conceivable that VEGF secreted by mesothelial
cells could exert its function on myofibroblasts with an endothelial
origin localized in the compact zone [5], inhibiting the mesen-
chymal phenotype by a mesenchymal to endothelial transition
and, consequently, inducing angiogenesis. However, the possible
autocrine effects of VEGF on MCs throughout the MMT process
have been overlooked. The expression of VEGFRs and Nrps by
MCs has been previously described [37]. Furthermore, it has been
shown that the expression pattern of VEGFRs and co-receptors
remains unaltered during the development of mesotheliomas [37].
In contrast, herein we show that throughout the mesenchymal
conversion of MCs, the expression of the receptors VEGFR-1 and
VEGFR-2 is down-regulated, and the expression of the co-
receptor Nrp-1 is induced. In addition, we demonstrate that the
ratio VEGF/Sema-3A increases sharply during the MMT process.
It is intriguing that the main receptor VEGFR2, involved in
VEGF-mediated proliferation, is repressed during MMT while the
expression of VEGF is strongly induced. It is also noteworthy that
the expression of Nrp-1, implicated in multiple cellular functions
including invasion, is induced during MMT in parallel with
VEGF. In this context, the expression of VEGF shows a significant
negative correlation with VEGFR2 and a significant positive
correlation with Nrp-1 (Figure S2). Interestingly, VEGF and
Nrp1 have a very similar distribution in MCs and during MMT,
when both proteins seem to internalize. However, VEGFR2 has
a different distribution. Thus, it is tempting to speculate that
VEGF might have divergent autocrine functions (e.g. proliferation
Figure 9. Effects of anti-VEGF and anti-Np1b blocking antibodies on the invasion capacity of mesothelial cells. (A) The MC invasion
capacity throughout in vitro and ex vivo MMT was analyzed by counting invading cells using a fluorescence microscope (n = 20). Data are depicted as
mean value 6 SE. Symbols show statistical differences between groups. (B and E) Effect of rhSema3A (n = 15), anti-VEGF (n = 10), anti-Np1a (n = 8),
anti-Np1b (n = 8) and IgG Isotype antibodies on the invasion capacity of omentum-derived MCs, either untreated (B) or treated with TGF-b1 plus IL-1b
(C); and on the invasion capacity of effluent-derived MCs with epithelioid (D) or non-epithelioid (E) phenotype. Bar graphics represent invasion
percentage of treatments over control cells. Numbers above histograms depict mean 6 SE. Symbols show statistical differences between groups.
doi:10.1371/journal.pone.0060776.g009
VEGFRs and Mesothelial to Mesenchymal Transition
PLOS ONE | www.plosone.org 15 April 2013 | Volume 8 | Issue 4 | e60776
Figure 10. Proposed model of the role of VEGF receptors and co-receptors during MMT induced by peritoneal dialysis. (A) General
scheme of VEGF receptors and co-receptors and the processes in which they are involved. (B) A normal peritoneum shows baseline VEGF receptors
and co-receptors expression, and normal VEGF and Sema-3A levels are secreted at the peritoneal cavity. During continuous peritoneal dialysis, MMT
takes place in the peritoneum. Denudation of MC monolayer, submesothelial fibrosis, and augmented vessel number begin to appear as visible signs
as a result of the MMT. In addition, MCs change the expression pattern of VEGFRs and co-receptors. At an initial stage, a higher proliferation rate of
MCs takes place, perhaps in order to repair the damage in the monolayer. However, MCs could fail to repair the peritoneal damage and MMT
progress. As a result of MMT progression, MCs increase secreted VEGF levels while its receptors are down-regulated and Nrp-1 co-receptor increases
at late stages of the MMT. The binding of VEGF to Nrp-1 would induce MC invasion to the submesothelial stroma. Therefore, MMT would determine
MC behaviour in terms of proliferation and invasion in response to VEGF.
doi:10.1371/journal.pone.0060776.g010
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vs. invasion) on MCs with either epithelial or mesenchymal
phenotype (Figure 10).
In this study, we demonstrate that MCs that have undergone an
in vitro or ex vivo MMT proliferate less than epithelial-like MCs.
These data are in agreement with previous results that demon-
strated that during EMT, there is an arrest of the cell cycle and the
cells acquire resistance to death [72]. Furthermore, we show that
blockade of endogenous VEGF inhibits the proliferation of
omentum MCs. Surprisingly, the proliferation capacity of
epithelioid MCs from effluents is only marginally affected by
VEGF-blocking antibody, in spite of producing similar amounts of
VEGF and expressing even greater levels of VEGFR2 than
omentum MCs. It is noteworthy that effluent MCs, still retaining
an epithelioid appearance, already show down-regulated expres-
sion of E-cadherin and induction of snail, suggesting that these
cells are already in early stages of the MMT process [4] (Figure 1).
Thus, our results indicate that endogenous VEGF plays a key role
in cellular proliferation in naı¨ve epithelial-like MCs, but not in
MCs undergoing the MMT process. On the contrary, we
demonstrate that MCs at any stage of the mesenchymal
conversion acquire an increased invasion capacity compared with
naı¨ve epithelial-like MCs. In addition, we show that the enhanced
invasion can be partially inhibited by treatment with anti-VEGF
or anti-Np-1b antibodies, and is almost completely abrogated by
a combination of both antibodies. These results strongly suggest
that the interaction of VEGF with Nrp-1 may have a role in MC
invasion (Figure 10).
Perhaps the most important aspect of the identification of the
MMT as a key event in peritoneal deterioration is that this process
can be modulated in vivo with a number of endogenous factors and
pharmaceutical agents [2]. In recent works, therapeutic strategies
were designed either to prevent or reverse the MMT process itself
or to reduce the MMT-inducing stimuli such as inflammation and
AGEs [7], [11], [12], [73–75]. It is important to point out that
MMT is a physiologic process necessary for wound healing during
PD-induced aggression of the peritoneum; therefore, it is plausible
that chronic blockade of MMT would result in inefficient tissue
repair. Thus, alternative therapeutic approaches should be
addressed to treat the consequences of the MMT, instead of the
MMT process itself. One of such consequences of MMT is the
increased cellular invasion. The identification of VEGF and Nrp-1
as important molecules controlling MC invasion might contribute
to the design of therapeutic approaches to avoid the accumulation
of MC-derived myofibroblasts in the submesothelial compact zone
(Figure 10).
Supporting Information
Figure S1 Effect on VEGF receptors and co-receptors
after TGF-b1 and IL-1b removal. (A–C) mRNA levels of
VEGF receptors/co-receptors were analyzed by quantitative RT-
PCR. The results represent the fold induction of mRNA
expression of VEGF receptors in omentum-derived MCs treated
with TGF-b1 plus IL-1 b (T+I 72 h) and omentum-derived MCs
after T+I withdrawal (T+I 72 h/24 h wo) compared with
untreated MCs (NT). (D–F) mRNA levels of mesenchymal
markers were analyzed by quantitative RT-PCR. Histograms
represent the expression of E-cadherin, collagen I and fibronectin
after the treatment with T+I (T+I 72 h) and after T+I withdrawal
(T+I 72 h/24 h wo) compared to non treated omentum-derived
MCs (NT).
(TIF)
Figure S2 Correlations between secreted levels of VEGF
and mRNA levels in effluent-derived MCs. (A) Negative
correlation between VEGF levels and VEGFR-2 mRNA expres-
sion levels (p = 0.004). (B) Negative correlation between VEGF
levels and Sema-3A mRNA expression (p = 0.04). (C) Positive
correlation between secreted VEGF and Nrp1 mRNA expression
levels (p,0.0001). Data are depicted as mean value 6 SE.
Symbols show statistical differences between groups.
(TIF)
Table S1 Oligonucleotides Sequences.
(DOC)
Table S2 Distribution of MCs Phenotype According to
Peritoneal Transport Rate.
(DOCX)
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